Resverlogix(加拿大)

Resverlogix

加拿大Resverlogixwww.resverlogix.comResverlogixCorp.(TSX:RVX)是一家心血管疾病臨床研究公司，公司擁有能夠調(diào)節(jié)蛋白質(zhì)形成的表觀遺傳學(xué)平臺技術(shù)。Resverlogix正在開發(fā)RVX-208——用于治療動脈粥樣硬化的同類小分子。RVX-208是正在進(jìn)行臨床試驗(yàn)的BET溴區(qū)結(jié)構(gòu)域抑制劑。出自Resverlogix表觀遺傳學(xué)藥物發(fā) 現(xiàn)平臺的新復(fù)合制劑通過抑制BET溴區(qū)結(jié)構(gòu)域而發(fā)揮作用，并有希望用來治療癌癥、自身免疫性疾病和神經(jīng)退行性疾病等多種病癥。Resverlogix的普通股在多倫多證券交易所交易(TSX:RVX)。ResverlogixCorp.isapubliclytradedbiotechnologycompany(TSX:RVX)engagedinthedevelopmentofnoveltherapiesforimportantglobalmedicalmarketswithsignificantunmetmedicalneeds.TheNexVas™PlaqueRegressionprogramistheCompany'sprimaryfocuswhichistodevelopnovelsmallmoleculesthatenhanceApoA-Iproduction.ThesevitaltherapiesarefocusedtoaddresstheburdenofatherosclerosisandotherimportantdiseasessuchasAcuteCoronarySyndrome,Alzheimer'sdisease,PeripheralArteryDiseaseandAutoimmunediseases.OurBusinessModelistoseekstrategicopportunitiesthroughearlyalliancepartnershipsthatare